Abstracts tagged "Dermatomyositis and interleukins (IL)"

Abstract Number: 879 • 2018 ACR/ARHP Annual Meeting
IL-31 Protein Expression in Lesional Skin Correlates with Itch in Dermatomyositis
Nithin Reddy^1,2, Majid Zeidi³ and Victoria P. Werth⁴, ¹Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ³Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Dermatomyositis (DM) is an inflammatory myopathy where itch is a major contributor to impaired quality of life. Previously, we have shown that a cytokine…
Abstract Number: 2146 • 2016 ACR/ARHP Annual Meeting
Clinical Characterization of Itch in Dermatomyositis and the Role of Increased Skin Interleukin-31
Hee Joo Kim^1,2,3, Diletta Bonciani^1,2,4, Sandra M. Pena², Janice Tiao², Padma Sahu^1,2, Muhammad M. Bashir^1,2 and Victoria P. Werth^1,2, ¹Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, The Republic of, ⁴Department of Surgery and Translational Medicine, Section of Dermatology, University of Florence, Florence, Italy
Background/Purpose: Interleukin-31 (IL-31) has been implicated in pruritus associated with various itchy skin diseases, including atopic dermatitis and cutaneous T cell lymphoma. While pruritus is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].